van Eijkeren Jan C H, Olie J Daniël N, Bradberry Sally M, Vale J Allister, de Vries Irma, Meulenbelt Jan, Hunault Claudine C
a National Institute for Public Health and the Environment , Bilthoven , The Netherlands.
b National Poisons Information Center, University Medical Center Utrecht , Utrecht , The Netherlands.
Clin Toxicol (Phila). 2016 Nov;54(9):833-839. doi: 10.1080/15563650.2016.1221508.
No kinetic models presently exist which simulate the effect of chelation therapy on lead blood concentrations in lead poisoning.
Our aim was to develop a kinetic model that describes the kinetics of dimercaptosuccinic acid (DMSA; succimer), a commonly used chelating agent, that could be used in developing a lead chelating model.
This was a kinetic modelling study. We used a two-compartment model, with a non-systemic gastrointestinal compartment (gut lumen) and the whole body as one systemic compartment. The only data available from the literature were used to calibrate the unknown model parameters. The calibrated model was then validated by comparing its predictions with measured data from three different experimental human studies.
The model predicted total DMSA plasma and urine concentrations measured in three healthy volunteers after ingestion of DMSA 10 mg/kg. The model was then validated by using data from three other published studies; it predicted concentrations within a factor of two, representing inter-human variability.
A simple kinetic model simulating the kinetics of DMSA in humans has been developed and validated. The interest of this model lies in the future potential to use it to predict blood lead concentrations in lead-poisoned patients treated with DMSA.
